The company “Chromis”, a joint venture between the Russian direct investment Fund (RDIF) and the group of companies “Chemrar”, signed an agreement with the Brazilian Axis BioTec for the supply of Russian drug Aviewer (favipiravir) for the treatment COVID-19 in Brazil.
Under the terms of the contract before the end of the current year the company “Chromis” put in Brazil a minimum of 100 thousand packages of the drug, in 2021 Brazil will acquire not less than 200 thousand packages.
Drug Aviewer included in the 7th version of the list of methodological recommendations for the prevention, diagnosis and treatment of new coronavirus infection, Ministry of health of Russia. From 10 June the drug is already in 50 regions of the Russian Federation. The drug efficacy proven in clinical studies, which were conducted in 35 health centers in Russia with the participation of 330 patients with a confirmed diagnosis COVID-19. The drug blocks the mechanisms of propagation of the coronavirus, relieves symptoms and shortens the disease by half compared with standard therapy.